can you take tirzepatide if you have gallstones After Gallbladder Removal: Safety and Management Guide Tirzepatide and Gallstone Risk: A

The global anti-obesity drug market is experiencing significant opportunities due to the growing prevalence of obesity and an increasing demand for safer, more effective, and patient-friendly treatments

The results of this study demonstrate that overall, combined cagrilintide and semaglutide therapy is well-tolerated and the safety profile is comparable to semaglutide alone

The oxygen-carrying function of hemoglobin is affected by [1]: pH lower pH (more acidic) in tissues increases the release of oxygen and stimulates the binding of carbon dioxide

The FDA has not approved these peptides for obesity treatment (FDA guidance on unapproved peptides)

This reflects the state of play as of early 2026: States that cover GLP-1s for obesity treatment (fee-for-service): Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, Washington approximately 13 states total as of January 2026